目的 應用基于鏈式方程的填補方法處理醫學研究中的數據缺失，并以填補后完全數據構建聯合指標的logistic判別函數，判斷其在前列腺癌的預測診斷中的應用價值。 方法 采用模擬研究，針對現實數據缺失情況模擬不同填補集結果，并以此對現實數據進行填補，以完整數據構建logistic判別，進行分析預測。 結果 填補結果隨著填補次數的增加而逐漸接近真實值并趨于穩定。聯合年齡、血清前列腺特異性抗原值、血流阻力指數及經直腸前列腺超聲檢查指標的logistic判別分析結果的靈敏度為82.39%，特異度為74.86%。 結論 聯合指標分析可提高前列腺癌的診斷預測水平，以減輕患者穿刺痛苦。
Prostate cancer ranks second among the causes of death of malignant tumors in middle-aged and elderly men. A considerable number of patients are not easily detected in early-stage prostate cancer. Although traditional imaging examinations are of high value in the diagnosis and staging of prostate cancer, they also have certain limitations. With the development of nuclear medicine instruments and molecular probes, molecular imaging is playing an increasingly important role in the diagnosis and treatment of prostate cancer. Positron emission tomography and computed tomography (PET/CT) using prostate-specific membrane antigen (PSMA) as a probe has gained increasing recognition. This article will review the latest progress in the application of PET/CT using probes for targeting PSMA to imaging and treatment of prostate cancer, in order to provide a theoretical basis for the application of probes for targeting PSMA in the diagnosis and treatment of prostate cancer.
Objective To comprehensively evaluate the association between TNF-α gene ?308 G/A polymorphism and the risk of prostate cancer. Methods A meta-analysis was performed to analyze the association between ?308 G/A polymorphism and the risk of prostate cancer risk. Results A total of 11 case-control studies (4 919 cases and 5 210 controls) were included in this meta-analysis. The result showed no statistically significant differences in all genotype distribution between prostate cancer cases and controls: dominant model (OR=1.11, 95%CI 0.90 to 1.36, P=0.33), recessive model (OR=0.91, 95%CI 0.70 to 1.18, P=0.47), GA versus GG (OR=1.11, 95%CI 0.90 to 1.37, P=0.33), AA versus GG (OR=0.92, 95%CI 0.71 to 1.20, P=0.55), A versus G (OR=1.07, 95%CI 0.91 to 1.26, P=0.39). In the subgroup analysis by ethnicity, no statistically differences were found between prostate cancer cases and controls. Conclusion This results of meta-analysis suggests that TNF-α gene –308G/A polymorphism may not be a risk factor of prostate cancer. Due to the limited quantity of the includied studies, further studies are needed to validate the above conclusion.
【摘要】 目的 觀察低頻超聲（20 kHz）輻照聯合靜脈注射微泡造影劑SonoVue對裸鼠前列腺癌（Du145）移植瘤的抑瘤效應，并探討其可能的抑瘤機制。 方法 通過細胞移植和瘤塊移植方法建立24只裸鼠前列腺癌Du145移植瘤模型，隨機分為超聲微泡組、單純超聲組、單純微泡組和對照組，每組各6只。超聲微泡組：尾靜脈注射0.2 mL SonoVue的同時對瘤體行20 kHz超聲輻照，輻照強度200 mW/cm2；單純超聲組：尾靜脈注射生理鹽水0.2 mL，同時超聲輻照2 min；單純微泡組：尾靜脈注射SonoVue 0.2 mL同時行假照，各組均隔天1次，共3次，對照組不做任何處理。治療后測量瘤體大小，繪制瘤體生長曲線，計算抑瘤率。首次治療后14 d剝離瘤體，通過光學顯微鏡、電子顯微鏡觀察腫瘤組織病理改變。免疫組織化學方法觀察CD34陽性染色血管，計算腫瘤微血管密度（micro vessel density，MVD），比較各組間MVD的差異。 結果 24只裸鼠均成功植瘤。治療后超聲微泡組瘤體體積均數明顯小于其他3組（Plt;0.05），抑瘤率為62.7%。光學顯微鏡下超聲微泡組瘤體組織大部分損傷壞死，電子顯微鏡下超聲微泡組腫瘤內微血管的內皮細胞損傷，線粒體腫大，基底膜斷裂。超聲微泡組瘤體內CD34陽性染色微血管數減少，其MVD值顯著低于其他各組。 結論 20 kHz低頻超聲輻照聯合微泡造影劑SonoVue可有效抑制裸鼠人前列腺癌移植瘤的生長，其抑瘤機制可能是通過超聲空化效應破壞腫瘤的微血管實現的。【Abstract】 Objective To investigate the anti-tumor effect induced by low-frequency ultrasound (20 kHz) radiation combined with intravenous injection of microbubbles on human prostate carcinoma xenograft in nude mice, and to discuss its probable mechanism. Methods Human prostate carcinoma xenograft model in 24 nude mice were established with human prostate carcinoma Du145 cells inoculation and sub-graft through mice, which were randomly divided into ultrasound+microbubble, ultrasound, microbubble, and control group, with 6 mice in each group. In the ultrasound+microbubble group, 0.2 mL SonoVue was injected intravenously, followed by 20 kHz ultrasound exposure of 200 mW/cm2 at every other day for 3 times totally. Mice in the ultrasound group and the microbubbles group were only treated with ultrasound radiation and microbubbles injection, respectively. The volume of gross tumors was measured, and tumor growth curve was drawn. The ratio of anti-tumor growth was calculated. The mice were sacrificed 14 days after the last ultrasound exposure. Specimens of the exposed tumor tissues were obtained and observed pathologically under light microscope and transmission electron microscope. CD34 positive vessels were counted in all the tumor slices by immunohistochemistry, and the micro-vessels density（MVD）of the tumor was also calculated. Results Du145 prostate tumor model was successfully established in all the mice. The average gross tumor volume of the ultrasound+microbubble group was significant lower compared with the other two groups after treatment (Plt;0.05), and the ratio of anti-tumor growth was 62.7%. Histological examination showed signs cell injury in the ultrasound+microbubble group. Electron microscopic examination revealed that the endothelium of vessels in the tumor was injured. The amount of CD34 positive vessels and MVD of the ultrasound+microbubble group was less than that of the other two groups. Conclusion The low-frequency ultrasound of 20 kHz exposure combined with microbubbles can be used to ablate human prostate carcinoma xenograft in nude mice, which is probably realized through micro-vessels destroyed by cavitation effect of ultrasound.
ObjectiveTo systematically review the correlation between Survivin expression and prostate cancer, as well as its clinicopathologic features in Chinese population. MethodsSuch databases as PubMed, EMbase, CBM, CNKI, VIP and WanFang Data were electronically searched from inception to November, 2015 to collect case-control studies about the correlation between Survivin expression and prostate cancer, as well as its clinically pathologic characteristics in Chinese population. Two reviewers independently screened literature, extracted data and assessed the methodological quality of included studies. Then, meta-analysis was performed using RevMan 5.3 software. ResultsA total of 32 case-control studies were included, involving 1613 prostate cancer cases, 708 benign prostatic hyperplasia cases, and 93 controls. The results of meta-analysis showed that the prostate cancer group had a higher Survivin expression level when compared with the benign prostatic hyperplasia group (OR=32.95, 95% CI 19.88 to 54.63, P<0.00001) or the control group (OR=75.78, 95% CI 26.97 to 212.98, P<0.00001). Moreover, the expression level of Survivin was higher in the low and medium differentiation group than in the high differentiation group (OR=4.45, 95% CI 3.13 to 6.32, P<0.00001), higher in the stage of C+D than in the stage of A+B (OR 5.42, 95% CI 2.91 to10.10, P<0.00001), and higher in the prostate cancer with lymph node metastasis than in the prostate cancer without lymph node metastasis (OR 4.07, 95% CI 2.91 to 10.10, P<0.00001). ConclusionCurrent evidence indicates that the expression level of Survivin is significantly correlated with prostate cancer and its clinicopathologic features in Chinese population. Due to the limited quantity and quality of included studies, above conclusions need to be verified by conducting more high quality studies.
目的 探討在恥骨后前列腺癌根治術中尿控功能和性功能保護的手術技巧和療效。 方法 2001年8月-2010年1月，行恥骨后前列腺癌根治術21例，其中2例經腹腔鏡施行。均早期控制縫扎背靜脈復合體，并妥善處理前列腺尖和尿道。21例通過保護控尿神經、保護尿道橫紋括約肌等措施，保護尿控功能；17例通過保留神經血管束技術（12例保留雙側，5例僅保留一側）保護性功能。 結果 手術均成功完成，無圍術期嚴重并發癥。2周拔出尿管后，排尿通暢，無尿道狹窄。手術后3、12個月內恢復尿控能力分別為：6例、13例，持續性輕-中度尿失禁2例。21例中，手術前勃起功能正常，并于手術中保留神經血管束17例，手術后3、12個月內勃起功能恢復分別為：2、8例，4例勃起功能減弱，3例不能勃起。手術后病理報告均為前列腺腺癌，未侵及精囊．膀胱頸，雙側淋巴結陰性。后尿道切緣陽性1例。手術后6、24、54個月各有1例出現生化復發。 結論 精細解剖并注意手術技巧，可有效保護性功能和尿控功能，并達到腫瘤根治的療效。
The incidence of prostate cancer ranks the second in malignant tumors among elderly males. Multi-parametric MRI (Mp-MRI) is an important mean for detection, staging, and grading of prostate cancer. In order to standardize the collection, interpretation, and reporting of prostate MRI data, the European Urogenital Radiology Society launched the Prostate Imaging Reporting and Data System (PI-RADS) in 2012. Due to some limitations in the application process, the Joint Committee of the American Society of Radiology and the European Society of Radiology issued an updated version of PI-PADS V2 in 2014. In recent years, some studies have been carried out on the effectiveness, accuracy, and consistency of the diagnosis of prostate cancer. This article will review the application and research status of PI-RADS V2 system in the diagnosis of Mp-MRI for prostate cancer.